|
1
|
Spira AI and Ettinger DS: The use of
chemotherapy in soft-tissue sarcomas. Oncologist. 7:348–359. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matushansky I, Charytonowicz E, Mills J,
Siddiqi S, Hricik T and Cordon-Cardo C: MFH classification:
Differentiating undifferentiated pleomorphic sarcoma in the 21st
Century. Expert Rev Anticancer Ther. 9:1135–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Le Doussal V, Coindre JM, Leroux A, Hacene
K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM and Contesso
G: Prognostic factors for patients with localized primary malignant
fibrous histiocytoma: A multicenter study of 216 patients with
multivariate analysis. Cancer. 77:1823–1830. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M,
et al: Broad spectrum and potent antitumor activities of YM155, a
novel small-molecule survivin suppressant, in a wide variety of
human cancer cell lines and xenograft models. Cancer Sci.
102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ren YQ, Zhang HY, Su T, Wang XH and Zhang
L: Clinical significance of serum survivin in patients with
pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci.
18:3063–3068. 2014.PubMed/NCBI
|
|
6
|
Caldas H, Holloway MP, Hall BM, Qualman SJ
and Altura RA: Survivin-directed RNA interference cocktail is a
potent suppressor of tumour growth in vivo. J Med Genet.
43:119–128. 2006. View Article : Google Scholar
|
|
7
|
Vischioni B, van der Valk P, Span SW,
Kruyt FA, Rodriguez JA and Giaccone G: Nuclear localization of
survivin is a positive prognostic factor for survival in advanced
non-small-cell lung cancer. Ann Oncol. 15:1654–1660. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
10
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy: Fulfilled promises and open
questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Span PN, Sweep FC, Wiegerinck ET,
Tjan-Heijnen VC, Manders P, Beex LV and de Kok JB: Survivin is an
independent prognostic marker for risk stratification of breast
cancer patients. Clin Chem. 50:1986–1993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trieb K, Lehner R, Stulnig T, Sulzbacher I
and Shroyer KR: Survivin expression in human osteosarcoma is a
marker for survival. Eur J Surg Oncol. 29:379–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu YF, Liang XJ, Liu YY, Gong W, Liu JX,
Wang XP, Zhuang ZQ, Guo Y and Shen HY: +Antisense oligonucleotide
targeting survivin inhibits growth by inducing apoptosis in human
osteosarcoma cells MG-63. Neoplasma. 57:501–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang X, Da M, Zhuang Z, Wu W, Wu Z, Wu Y
and Shen H: Effects of Survivin on cell proliferation and apoptosis
in MG-63 cells in vitro. Cell Biol Int. 33:119–124. 2009.
View Article : Google Scholar
|
|
15
|
Lechler P, Renkawitz T, Campean V,
Balakrishnan S, Tingart M, Grifka J and Schaumburger J: The
antiapoptotic gene survivin is highly expressed in human
chondrosarcoma and promotes drug resistance in chondrosarcoma cells
in vitro. BMC Cancer. 11:1202011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taubert H, Kappler M, Bache M, Bartel F,
Köhler T, Lautenschläger C, Blümke K, Würl P, Schmidt H, Meye A, et
al: Elevated expression of survivin-splice variants predicts a poor
outcome for soft-tissue sarcomas patients. Oncogene. 24:5258–5261.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kelly RJ, Thomas A, Rajan A, Chun G,
Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et
al: A phase I/II study of sepantronium bromide (YM155, survivin
suppressor) with paclitaxel and carboplatin in patients with
advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Satoh T, Okamoto I, Miyazaki M, Morinaga
R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y,
et al: Phase I study of YM155, a novel survivin suppressant, in
patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheson BD, Bartlett NL, Vose JM,
Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos
KP: A phase II study of the survivin suppressant YM155 in patients
with refractory diffuse large B-cell lymphoma. Cancer.
118:3128–3134. 2012. View Article : Google Scholar
|
|
21
|
Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki
H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and
Tsubura A: Novel cell lines established from a human myxoid
malignant fibrous histiocytoma arising in the uterus. Cancer Genet
Cytogenet. 127:7–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakatani T, Marui T, Yamamoto T, Kurosaka
M, Akisue T and Matsumoto K: Establishment and characterization of
cell line TNMY1 derived from human malignant fibrous histiocytoma.
Pathol Int. 51:595–602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okada Y, Akisue T, Hara H, Kishimoto K,
Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y and Kurosaka
M: The effect of bevacizumab on tumour growth of malignant fibrous
histiocytoma in an animal model. Anticancer Res. 30:3391–3395.
2010.PubMed/NCBI
|
|
24
|
Radaelli S, Stacchiotti S, Casali PG and
Gronchi A: Emerging therapies for adult soft tissue sarcoma. Expert
Rev Anticancer Ther. 14:689–704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ranieri G, Mammì M, Donato Di Paola E,
Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M
and De Sarro G: Pazopanib a tyrosine kinase inhibitor with strong
anti-angiogenetic activity: A new treatment for metastatic soft
tissue sarcoma. Crit Rev Oncol Hematol. 89:322–329. 2014.
View Article : Google Scholar
|
|
26
|
Santoro A, Tursz T, Mouridsen H, Verweij
J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et
al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide
in first-line treatment of advanced soft tissue sarcomas: A
randomized study of the European Organization for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin
Oncol. 13:1537–1545. 1995.PubMed/NCBI
|
|
27
|
Sanna MG, da Silva Correia J, Ducrey O,
Lee J, Nomoto K, Schrantz N, Deveraux QL and Ulevitch RJ: IAP
suppression of apoptosis involves distinct mechanisms: The
TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol.
22:1754–1766. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nachmias B, Ashhab Y and Ben-Yehuda D: The
inhibitor of apoptosis protein family (IAPs): An emerging
therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adida C, Berrebi D, Peuchmaur M,
Reyes-Mugica M and Altieri DC: Anti-apoptosis gene, survivin, and
prognosis of neuroblastoma. Lancet. 351:882–883. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin CY, Hung HC, Kuo RC, Chiang CP and Kuo
MY: Survivin expression predicts poorer prognosis in patients with
areca quid chewing-related oral squamous cell carcinoma in Taiwan.
Oral Oncol. 41:645–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reed JC: The Survivin saga goes in vivo. J
Clin Invest. 108:965–969. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marusawa H, Matsuzawa S, Welsh K, Zou H,
Armstrong R, Tamm I and Reed JC: HBXIP functions as a cofactor of
survivin in apoptosis suppression. EMBO J. 22:2729–2740. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fukuda S and Pelus LM: Survivin, a cancer
target with an emerging role in normal adult tissues. Mol Cancer
Ther. 5:1087–1098. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zaffaroni N, Pennati M, Colella G, Perego
P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG:
Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell Mol Life Sci.
59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Granziero L, Ghia P, Circosta P, Gottardi
D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M and
Caligaris-Cappio F: Survivin is expressed on CD40 stimulation and
interfaces proliferation and apoptosis in B-cell chronic
lymphocytic leukemia. Blood. 97:2777–2783. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rödel F, Hoffmann J, Distel L, Herrmann M,
Noisternig T, Papadopoulos T, Sauer R and Rödel C: Survivin as a
radio-resistance factor, and prognostic and therapeutic target for
radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005.
View Article : Google Scholar
|
|
42
|
Kappler M, Köhler T, Kampf C,
Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C,
Rieber EP, Schmidt H, et al: Increased survivin transcript levels:
An independent negative predictor of survival in soft tissue
sarcoma patients. Int J Cancer. 95:360–363. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tsuji N, Asanuma K, Kobayashi D, Yagihashi
A and Watanabe N: Introduction of a survivin gene-specific small
inhibitory RNA inhibits growth of pancreatic cancer cells.
Anticancer Res. 25B:3967–3972. 2005.
|
|
44
|
Wang F, Bai HR, Wang J, Bai YZ and Dou CW:
Glioma growth inhibition in vitro and in vivo by single chain
variable fragments of the transferrin receptor conjugated to
survivin small interfering RNA. J Int Med Res. 39:1701–1712. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang J-W, Liu Y, Tian H and Zhang W:
Effect of survivin-siRNA on drug sensitivity of osteosarcoma cell
line MG-63. Chin J Cancer Res. 22:68–72. 2010. View Article : Google Scholar
|
|
46
|
Zaffaroni N, Pennati M and Daidone MG:
Survivin as a target for new anticancer interventions. J Cell Mol
Med. 9:360–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ling X, Bernacki RJ, Brattain mg and Li F:
Induction of survivin expression by taxol (paclitaxel) is an early
event, which is independent of taxol-mediated G2/M arrest. J Biol
Chem. 279:15196–15203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Faversani A, Vaira V, Moro GP, Tosi D,
Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC and Bosari S:
Survivin family proteins as novel molecular determinants of
doxorubicin resistance in organotypic human breast tumors. Breast
Cancer Res. 16:R552014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tolcher AW, Quinn DI, Ferrari A, Ahmann F,
Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of
YM155, a novel small-molecule suppressor of survivin, in
castration-resistant taxane-pretreated prostate cancer. Ann Oncol.
23:968–973. 2012. View Article : Google Scholar
|
